A retrospective US study yesterday in JAMA Network Open suggests that adult COVID-19 patients taking a selective serotonin reuptake inhibitor (SSRI) antidepressant—particularly fluoxetine hydrochloride (Prozac) or fluvoxamine maleate (Luvox)—were less likely to die of their infections than those not taking the drugs.SSRIs, which are used for treating depression and other psychological conditions, are one of the most commonly prescribed, widely available antidepressant classes.University of California San Francisco (UCSF) and Stanford University researchers analyzed information from the Cerner Real World COVID-19 electronic health record database of 83,584 patients who tested positive for COVID-19 from January to September 2020 at 87 US